The TaqIB polymorphism in intron 1 of the cholesteryl ester transfer protein (CETP) gene is associated with plasma CETP concentration, high-density lipoprotein cholesterol (HDL-C) and coronary artery disease (CAD). These associations are generally thought to arise from linkage disequilibrium between TaqIB and (an)other functional polymorphism(s). To identify putative functional sites, we investigated phenotypic associations of TaqIB and four tightly linked polymorphisms (novel À2708G!A and þ784CCC!A, and previously identified À971G!A and À629C!A) in 709 males with CAD (REGRESS). In addition to genotype analyses, a novel method to estimate haplotype effects was used to examine the individual and joint effects of these DNA variants on CETP concentration and HDL-C. All polymorphisms were associated with CETP concentration and HDL-C, except for À971 with HDL-C. Stepwise regression and haplotype analyses indicated that only À629 was independently associated with HDL-C. Similar analyses additionally indicated that À2708 and À629 were independently associated with CETP concentration, whereby the most frequent alleles acted in a cumulative manner. Nonetheless, detailed haplotype analysis revealed that a 3-polymorphism haplotype model consisting of À2708, À629 and À971 explained the variation in CETP concentration best. The involvement of À971 could be due to interaction effects that were observed between À971 and both À629 (P < 0.001) and À2708 (P ¼ 0.047). In conclusion, the TaqIB polymorphism is not instrumental in determining CETP or HDL-C levels, but is a marker for the À629 promoter variant. Our analyses, furthermore, indicate that the À2708 and À971 polymorphisms are likely to play a role in determining CETP concentration.
INTRODUCTION
Cholesteryl ester transfer protein (CETP) plays a central role in human lipoprotein metabolism. This 74 000 kDa plasma protein shuttles cholesteryl esters (CE) from high-density lipoprotein (HDL) to Apolipoprotein B (ApoB) containing lipoproteins in exchange for triglycerides (1) . Human CETP deficiency is characterized by very high HDL cholesterol (HDL-C) levels, but the role of CETP in determining HDL-C in the general population and how it may modulate the risk for coronary artery disease (CAD) is unclear (2) (3) (4) . Through its function in the reverse cholesterol transport (RCT) pathway, CETP is potentially anti-atherogenic, because it may facilitate the removal of excess cholesterol from the body via LDLreceptor mediated uptake in the liver and excretion into the bile. On the other hand, as CETP may lower the concentration of atheroprotective HDL-C, it is often considered to be pro-atherogenic (4) (5) (6) (7) .
The CETP gene is highly polymorphic; many mutations in both coding and non-coding regions have been described (8) (9) (10) (11) . Of these, the TaqIB polymorphism in intron 1 has been studied extensively due to associations with HDL-C (12-16), but so far the significance of the effects of this polymorphism is poorly understood (17) . Significant associations of the wild-type B1B1 genotype (TaqI restriction site present) with higher plasma CETP concentration and/or CETP activity and lower HDL-C were found in several large studies (11, 14, 16, 18) , but this is not consistently observed (12, (19) (20) (21) . Furthermore, it has been reported that the effects of TaqIB on the above parameters are gender dependent and also influenced by alcohol use, body mass index (BMI) and insulin levels (10) (11) (12) 16, 22, 23) . In addition to the associations of TaqIB with parameters in lipid metabolism, this polymorphism has been shown to be associated with the risk of CAD. In the Framingham Offspring Study, the B2 allele was associated with a reduced risk of coronary heart disease in men (16) , and recently this was also shown in the Veterans Affair HDL-C Intervention Trial (VA-HIT) (24) . Furthermore, it was shown that TaqIB predicted the response to lipid lowering therapy with respect to progression of coronary atherosclerosis, i.e. pravastatin was shown to be effective in retarding the progression only in men carrying the B1 allele (14) .
The TaqIB polymorphism concerns a single nucleotide polymorphism (SNP) that affects the 277th nucleotide of intron 1 (902 bp). Due to its location, it is assumed that this SNP is not part of a functional regulatory site, but that it is a marker for another functional site or possibly multiple linked polymorphisms with independent effects (17) . To date, several associations of the TaqIB site with other CETP variants have been investigated. A number of mutations resulting in amino acid substitutions, namely A373P, I405V and R451Q, were found to be independent variations from the TaqIB polymorphism with respect to effects on HDL-C and CETP activity (9, 11, 15, 20, 25) . However, recently a promoter variant of the CETP gene was identified at position À629 relative to the transcription start (26) . In the ECTIM study, the less common A allele was associated with lower plasma CETP concentration (P < 0.0001) and independently with increased HDL (P < 0.0001) (11, 26) . Moreover, a direct effect of variation at À629 on CETP gene expression was established in vitro using reporter gene expression in liver cells (26) . Genotype analysis in several cohorts showed that the À629 polymorphism was almost fully concordant with TaqIB, indicating that this variation is a good candidate to explain the effects observed for the TaqIB polymorphism (11, 20, 26) .
To determine whether the TaqIB polymorphism itself is putatively functional in determining CETP and HDL-C levels or a marker for other strongly linked functional variations, we performed extensive genotype and haplotype association analyses of TaqIB and four variants between À3 and þ1 kb in the CETP gene that all were in strong linkage disequilibrium. For this analysis, we used the REGRESS cohort consisting of men with angiographically proven CAD, in which we previously observed associations of TaqIB with CETP concentration, HDL-C, progression of atherosclerosis and response to pravastatin treatment (14, 27) . We hypothesized that in a cluster of tightly linked polymorphisms the gene variation, which is least associated with phenotypic traits, is unlikely to be functional in determining these parameters. Furthermore, haplotype analysis may reveal the effects of single sites within a certain haplotype when the sample size allows comparison of haplotypes that are dissimilar at only one site. Therefore, a novel method that enabled the inclusion of multiple heterozygotes, thereby increasing the sample size and power of the analysis, was used to estimate haplotype effects (28) Our results show that not the TaqIB polymorphism, but the closely linked À629 promoter polymorphism and a novel promoter polymorphism located at À2708 are independent predictors of the variation in CETP concentration, and involvement of the À971 polymorphism through an interaction effect with À629.
RESULTS

Identification of novel polymorphisms and linkage disequilibrium with TaqIB
The complete DNA sequence between À3060 bp and þ1060 bp of the CETP gene was determined in five TaqIB B1B1 and five B2B2 individuals. The consensus of these sequences differed slightly from previously published GenBank sequences (M32992, AF027656, U71187 and U85248), and was therefore submitted to the GenBank under accession number AY172980. Analysis of this DNA sequence revealed the presence 16 single nucleotide polymorphisms (SNPs) including TaqIB, a GAAA repeat of variable length, one variable T-stretch, one deletion mutation, and one combined substitution and deletion (Fig. 1 ). Of these, eight variations were almost concordant with variation at the TaqIB site. Another three gene variants were less frequent and almost concordant with each other, but not with TaqIB. Finally, five variations were detected only once, and therefore not further studied.
Using the REGRESS population, we further investigated the linkage disequilibrium (LD) between the TaqIB polymorphism and four possibly concordant polymorphisms that may be functional in regulating CETP gene expression. These included the upstream most distant À2708G!A polymorphism and the þ784CCC!A polymorphism located 360 bp downstream of TaqIB, of which TRANSFAC analysis indicated that these nucleotide changes might interfere with binding sites of transcription factors involved in regulation of the ApoB and ApoE gene, and therefore may alter CETP gene expression (not shown) (29) (30) (31) . Furthermore, the previously investigated À629C!A and À971G!A promoter polymorphisms, of which (non)functionality in regulating CETP gene expression in liver cells was already established, were also included (26, 32) . Allele frequencies of these loci are given in Table 1 . All pairwise polymorphism combinations were in significant (P < 0.001) LD (Table 1 ). The strongest pairwise LD was found between the TaqIB polymorphism and the À629 polymorphism (D 0 ¼ 0.98), followed by TaqIB with À2708 and þ784. In particular, the least frequent alleles of all polymorphisms were tightly linked to each other. Furthermore, the À971 polymorphism showed the weakest LD with TaqIB and all other variants.
Association of genotypes with CETP concentration and HDL-C
A total of 709 patients were genotyped for all five aforementioned polymorphisms, and in this group baseline CETP concentration and HDL-C were determined in 532 and 702 patients, respectively. Using univariate analysis, these five tightly linked gene variants had similar effects on baseline CETP concentration and HDL-C. Homozygous carriers of the most frequent alleles (denoted as 'þ') had significantly higher CETP concentration and lower HDL-C levels compared to carriers of the least frequent alleles (denoted as 'À'), except for À971 and HDL-C (Table 2) . These inverse associations with CETP concentration and HDL-C were independent, since baseline CETP concentration and HDL-C were not significantly correlated in the REGRESS population (Pearson r ¼ À0.078, P ¼ 0.072). Single polymorphism genotype analysis showed that the À629 promoter polymorphism explained the highest portion of the variance in CETP concentration (7.9%), followed by the distant promoter polymorphism at À2708 (7.0%) and TaqIB (6.0%). The largest portion of variance in HDL-C was explained by À629 (4.6%) and TaqIB (3.9%), whereas À2708 explained only 2.6% of the variance. Multiple polymorphism genotype analysis revealed that all five polymorphisms together in a model with no (¼ main effects only) and with all possible interactions (¼ fully saturated model) accounted for 10.3 and 16.2% of the variation in CETP concentration, respectively. For HDL-C, these models explained 5.5 and 9.8% of the total variation, respectively.
To investigate whether the phenotypic associations of these five polymorphisms, in particular the TaqIB polymorphism, could be attributed to confounding effects of one or more functional polymorphisms, both backward stepwise regression analysis using genotypes and haplotype analyses (see below) were performed. For CETP concentration, the backward All polymorphisms were in significant linkage disequilibrium ( P < 0.001).
regression procedure resulted in a model with independent effects of the À629 (P ¼ 0.0025) and À2708 (P ¼ 0.025) promoter polymorphisms and baseline triglycerides (P ¼ 0.011) as covariate. In the first selection step, the À971 polymorphism was removed, consecutively followed by the TaqIB and the þ784 polymorphisms. For HDL-C, this procedure resulted in a model consisting of the À629 genotype (P < 0.0001) with baseline triglycerides (P < 0.0001) and BMI (P < 0.001) as covariates. During the selection steps, the þ784 polymorphism was removed first, consecutively followed by TaqIB, À971 and À2708.
Haplotypes and effects on CETP and HDL-C concentration
Haplotypes were assigned to all individuals as described in the Materials and Methods section. The inclusion of both unambiguous and ambiguous individuals greatly increased the number of observations in the data set (397 patients (56%) were heterozygous at two or more loci). Of the 32 possible five polymorphism (5-pol) haplotypes, 20 were estimated to be present. Remarkably, the haplotype consisting of the most frequent alleles of each polymorphism (À2708G/À971G/ À629C/TaqIB B1(G)/þ784CCC; further referred to as 'þþþþþ') and the haplotype consisting of the least frequent alleles (all A; further referred to as 'ÀÀÀÀÀ') were most prevalent with estimated relative frequencies of 0.4096 and 0.2779, respectively. In accordance with the genotype analyses, the 'þþþþþ' haplotype had significantly higher CETP concentration and lower HDL-C compared with the 'ÀÀÀÀÀ' haplotype. This 5-pol haplotype model explained 16.8% of the variation in CETP concentration and 6.3% of the variation in HDL-C. In Table 3 , the effects of the five most frequent 5-pol haplotypes on CETP concentration and HDL-C are shown. Of the 15 remaining haplotypes estimated to be present at a frequency of 0.0258 or below, too few observations were present to observe significant effects. The CETP concentration of the 'ÀÀÀÀÀ' haplotype was significantly lower than all other compared 5-pol haplotypes. Furthermore, a significant difference in effect on CETP concentration was found for the 'þÀþþþ' (À2708G/À971A/À629C/TaqIB B1(G)/þ784CCC) and 'þÀÀþþþ' (À2708G/À971A/À629A/TaqIB B1(G)/ þ784CCC) haplotypes, which only differ at the À629 site.
Regarding HDL-C, the 'ÀÀÀÀÀ' haplotype had significantly higher HDL-C than the 'þþþþþ' haplotype and the 'þÀþþþ' haplotype. No significant differences in HDL-C were observed between haplotypes differing at a single site. These results did not change when covariates were added to these 5-pol haplotype models, as the estimated effects were essentially the same.
To determine which haplotype model would fit the observed CETP and HDL-C concentrations best, the AIC for all possible 'one', two, three, four and five polymorphism haplotype models were calculated. Based on these AIC (Table 4) , the best fitting haplotype model for CETP concentrations included the À2708, À971 and À629 polymorphisms, and the next three best scoring models all contained these three polymorphisms. In contrast, the best 'haplotype' model for HDL-C only consisted of the À629 polymorphism. Although inclusion of covariates in the haplotype models increased the AIC of the individual models, it did not substantially influence the ranking of the haplotype models.
Since the backward stepwise regression analysis indicated independent effects of the À2708 and À629 polymorphisms on CETP concentration, and the haplotype analysis pointed towards an additional contribution of the À971 variation, the effects of these three polymorphisms on CETP concentration were further analyzed. Remarkably, a 2-pol haplotype model that consisted of À971 and À629 best explained the variation in CETP concentration with an r 2 of 11.4, whereas the À2708 and À629 model explained 8.2% of the variation in CETP. The effects of the different haplotypes of these models on CETP concentration are depicted in Figure 2 . The À2708 and À629 haplotype model confirmed the independent effects on CETP concentration of these polymorphisms observed in the genotype analyses (see Fig. 2A ). The most frequent À2708G and À629C alleles acted cumulatively in raising CETP concentration, as was indicated by the intermediate CETP concentration levels of the discordant À2708G/À629A (þÀ) and À2708A/À629C (Àþ) haplotypes compared with the À2708G/À629C (þþ) and À2708A/À629A (ÀÀ) haplotypes. The difference in CETP concentration was significant for the À2708G/À629A (þÀ) haplotype compared with 'þþ' and 'ÀÀ' (P ¼ 0.001 and P ¼ 0.034, respectively). For the À2708A/À629C (Àþ) the same trend was observed, but this was not significant (versus 'þþ' P ¼ 0.072, and versus 'ÀÀ' P ¼ 0.052), which could probably be explained by the lower number of observations of this haplotype. Interestingly, in the À971 and À629 model, an interaction effect was observed between the polymorphisms (see Fig. 2C ). The least frequent À971A allele in combination with the most frequent À629C allele (Àþ) resulted in significant raising of CETP concentration compared to the À971C/À629C (þþ) haplotype (P ¼ 0.002), while combination of À971A with the least frequent À629A allele (ÀÀ) significantly lowered the CETP concentration compared to À971C/À629A (þÀ) (P ¼ 0.002). This interaction effect was confirmed by multiple regression analysis of the À971 and À629 genotypes and their interaction was found to be highly significant (P < 0.001) (Fig. 2D) . A significant interaction was also observed between the À2708 and À971 polymorphisms (P ¼ 0.0468), which for their haplotypes is depicted in Fig. 2B .
Regarding HDL-C, the haplotype analysis confirmed the independent effect of the À629 polymorphism observed in the backward stepwise multiple regression. The second best haplotype model involved the À971 and À629 polymorphisms. However, no significant effect of the À971 polymorphism was found (see Fig. 2E ), nor was an interaction effect observed (P ¼ 0.191). A possible contribution of the TaqIB polymorphism in determining HDL-C was furthermore indicated by the AIC indices of the TaqIB 'I'-pol and À629 and TaqIB 2-pol haplotype models. The À629 and TaqIB 2-pol haplotype model revealed intermediate effects of the discordant À629A/TaqIB B1 (Àþ) and À629C/TaqIB B2 (þÀ) haplotypes on HDL-C compared with the À629C/TaqIB B1 (þþ) and À629A/TaqIB B2 (ÀÀ) haplotypes, but these were not significant (Fig. 2F) , nor was a significant interaction effect between these polymorphisms observed (P > 0.7).
Furthermore, all other 2-pol and 3-pol haplotype models were analyzed. No significant contributions of either TaqIB or þ784 in combination with À629 to CETP concentration or HDL-C were observed. However, TaqIB did show a significant effect on CETP concentration in combination with À2708G ('þþ' versus 'þÀ') and À971A ('Àþ' versus 'ÀÀ'). For þ784, only the latter was significant.
DISCUSSION
The CETP TaqIB polymorphism is associated with changes in plasma CETP concentrations, HDL cholesterol, and risk of CAD (11, 14, 16) . Because of its location in intron 1, TaqIB is not expected to directly influence CETP transcriptional regulation or RNA splicing, but more likely serves as a marker for (an)other polymorphism(s) that directly affect CETP gene regulation. We here set out to identify putative functional polymorphisms that are in strong LD with TaqIB, which may account for the observed phenotypic effects. For this, we performed extensive sequence analysis of the CETP gene promoter and intron 1 (À3 and þ1 kb relative to the transcriptional start), resulting in the identification of 15 novel polymorphisms. Second, we used extensive genotype analyses and a novel type of haplotype analysis to study the effects of four tightly to TaqIB linked DNA variants on CETP concentration and HDL-C in 709 male patients from the REGRESS cohort.
Polymorphisms and haplotypes
Of the 15 novel CETP gene variations we identified, eight were almost concordant with the TaqIB polymorphism in 10 individuals. Further analysis of the novel À2708 and þ784 polymorphisms, and the previously identified TaqIB, À971 and À629 polymorphisms in the REGRESS population, revealed the existence of two completely opposite haplotypes consisting of either the most or least frequent alleles (referred to as 'þþþ þþ' and 'ÀÀÀÀÀ') at the highest frequencies. Noteworthy, the five most frequent haplotypes accounted for 93% of all existing haplotypes, indicating that TaqIB is part of a limited number of well-conserved haplotypes. The observed concordance of the À971 and À629 polymorphisms and TaqIB is consistent with similar analyses in subsets of the ECTIM study and the OPERA cohort (11, 20, 32) . Others have reported a SNP in intron 7 located more than 8 kb downstream of the currently investigated sequence that was almost concordant with the TaqIB polymorphism in the ECTIM population (10, 11) . Together, these data suggest that TaqIB may be in tight linkage disequilibrium with an even greater number of nucleotide variations at the CETP gene locus, which, theoretically, could all account for the phenotypic effects observed for the TaqIB polymorphism. The 'þþþþþ' haplotype was associated with significantly lower HDL-C and higher CETP concentration, as was previously observed for both the TaqIB B1 (þ) and À629C (þ) alleles separately (11, 14, 25) . In the following sections we will discuss the contribution of each of the polymorphisms on CETP concentration and HDL-C starting with the polymorphism that has the largest effect, and we will discuss possible mechanisms that may explain the effects of these gene variations. Finally, we will evaluate the status of the TaqIB polymorphism.
Associations with CETP concentration and mechanism
The proportion of variance explained by the polymorphisms as assessed by univariate analysis (maximally 7.9%) and multivariate analyses (10.3 and 16.2%) indicates that more than one DNA variation and a possible interaction between these variations are responsible for the observed effect on CETP concentration. The À629 variant came forward as the best predictor of variation in CETP concentration in the genotype analysis and was always included in the best fitting haplotype models. Moreover, in every 2-pol haplotype model including À629, significant independent effects of this polymorphism on CETP concentration were observed. Finally, the strongest indication for independent effects of À629 polymorphism was provided by the 5-pol haplotype model, which showed that the mutant À629A (À) allele had a significant CETP concentration lowering effect when the 'þÀÀþþ' and 'þÀþþþ' haplotypes were compared. Surprisingly, the most distant promoter polymorphism located at À2708 was shown to be an independent determinant of CETP concentration in the stepwise regression procedure. From the 5-pol haplotype models, however, no information was obtained on a separate contribution of À2708, which is most likely due to the very strong linkage of the least frequent À2708A allele with all 'À' alleles of the other polymorphisms. On the other hand, the independent effect of this site was corroborated by the inclusion of this polymorphism in the best fitting haplotype models, and an independent effect of À2708 in the 2-pol haplotype analysis of À2708 and À629. In this model, the CETP lowering effect of the À2708A allele (À) constituted 72% of the effect observed for À629A (À), suggesting that À2708 and À629 comparably and cumulatively contribute to the variation in CETP concentration.
The À971 polymorphism scored very low in the genotype analyses, which together with its weak linkage disequilibria with all other variants suggested that this gene variation is not important for determining CETP levels. These findings are in agreement with the data of Le Goff and coworkers (32) , who observed a significant association of the À971 polymorphism with CETP concentration in the ECTIM population that disappeared upon correction for variation at the À629 and TaqIB sites. They furthermore showed that the À971 site is not functional in regulating CETP gene expression in liver cells (HepG2). Confusingly, À971 was found to be essential in the best scoring haplotype models, and further analysis revealed a strong interaction effect between the À971 and À629 polymorphisms on CETP concentration. A possible explanation for these discrepancies will be discussed below in a mechanistic context. Our haplotype analyses furthermore indicate that both the TaqIB and þ784 polymorphisms do not significantly contribute to the variation in CETP concentration, but that the associations of these polymorphisms observed in the genotype and 2-pol haplotype analyses can be attributed to the linkage disequilibria of these variants with the À2708 and À629 polymorphisms.
All polymorphisms that were found to contribute to variations in CETP concentration are located in the promoter and may therefore be located in cis-acting elements that are functional in regulating the transcriptional activity of the CETP gene. The significant CETP-lowering effect of the À629A allele as observed in our study is in accordance with the in vitro data of Dachet et al. (26) . They showed that in HepG2 cells the expression of a reporter gene containing the least frequent À629A allele was 25% lower compared with the most frequent À629C allele. Thus, our finding that the À629 polymorphism accounts for 7.9% of the variation in plasma CETP concentration is likely to be the result of a differential expression of both alleles in the liver, which is the major but not the only site of CETP synthesis (1, 33) . Since À971 and À629 are in close proximity to each other, one could envision numerous scenarios of interplay between transcription factors binding to these sites that would explain the observed interaction effect. However, Le Goff et al. (32) did not observe specific binding of transcription factors to either variation at À971 in HepG2 cells. The discrepancy between the in vitro data and the association studies might be explained by the fact that the liver is not the only site of CETP synthesis. Adipose tissue was reported to account for a considerable portion of CETP synthesis and in this respect the action of À971 might be adipose tissuespecific, which may result in variations in plasma CETP concentration (33) (34) (35) (36) (37) . Regarding the À2708 polymorphism, our results indicate that this variation acts independently in determining CETP concentration, which could possibly be explained by the interference of this site with an enhancer or silencer element involved in the transcriptional regulation of the CETP gene. Alternatively, the possibility remains that À2708 and À971 themselves are not functional, but markers for yet other linked functional polymorphism located elsewhere that were not investigated in this study. To determine this, (further) functional analysis of these sites is crucial.
Associations with HDL-C and mechanism
In the univariate analyses, the À629 and TaqIB polymorphisms accounted for 4.6% and 3.9% of the variation in HDL-C, respectively. In the ECTIM study cohort of myocardial infarction (MI) survivors 5.58% of the variation in HDL-C was explained by the À629 polymorphism (11), while the TaqIB polymorphism only accounted for $1% of the variation in HDL-C in the Framingham Offspring Study (16) . This indicates that the contribution of CETP gene variants to HDL-C variation may substantially differ in diseased and healthy populations. In the REGRESS cohort, both stepwise regression genotype analysis and testing of all haplotype models on HDL-C indicated that only the À629 polymorphism was an independent determinant of the variation in HDL-C. This, however, could not be confirmed by comparison of the effects of two haplotypes, which only differed at the À629 site. Although the À2708 polymorphism was shown to play a major role in determining CETP concentration, none of our results pointed towards a contribution of this SNP to HDL-C. With respect to À971, the recent analysis in the ECTIM study showed significant associations of this site with HDL-C, even when corrected for the À629 and TaqIB polymorphisms (32) . Our results, in contrast, do not indicate any association of the À971 site with HDL-C. An explanation for this discrepancy will be discussed in a broader context below. Regarding TaqIB, however, we observed a trend towards a possible involvement of this site, as was tentatively inferred by the ranking of the best haplotype models for HDL-C, but this needs further confirmation. Therefore, from these results it can be concluded that of the investigated sites, the À629 polymorphism is the only independent determinant of HDL-C.
The critical role of CETP in HDL metabolism is illustrated by genetic CETP deficiency, in which loss of CETP activity is associated with strongly elevated HDL-C levels (2). The novel CETP inhibitor JTT-705 was furthermore shown to raise HDL-C levels in cholesterol-fed rabbits and humans (38, 39) . Epidemiological studies, however, consistently indicate that the associations between CETP gene variants and HDL-C are independent of CETP concentration or activity, implying that these associations are not mediated through CETP (10, 11, 16 , this study). This absence of a direct association between CETP concentration and HDL-C levels in epidemiological studies may be related to (genetic) variations in other proteins involved in HDL metabolism (40) . In addition, multiple factors are known to have heterogeneous effects on CETP and HDL-C such as age, gender and lifestyle differences in populations of patients and healthy subjects. Together, these factors may be responsible for obscuring the effects of variations in plasma CETP concentration on HDL-C levels. It could, therefore, be argued that finding associations between the À629 polymorphism and both CETP and HDL-C concentration despite these confounding genetic and environmental factors, is indicative of a direct involvement of this site in determining HDL-C levels mediated through variations in CETP concentration. However, the two other polymorphisms that were shown to affect CETP concentration did not influence HDL-C. Moreover, the haplotype analysis suggested a possible role of TaqIB polymorphism for determining HDL-C, which was found to be non-functional in determining CETP concentration. These latter observations rather suggest that the mechanism by which these variations in the CETP gene influence HDL-C does not involve CETP. Le Goff et al. (32) propose the existence of another as yet unidentified polymorphism linked to À971, À629 and TaqIB, which simultaneously modulates HDL-C and CETP concentration. We here show that, of the five investigated polymorphisms, the À629 site is the only polymorphism that is independently associated with HDL-C, but the mechanism that can explain these associations remains unclear.
Concluding remarks
As mentioned above, in contrast to the data published by Le Goff and co-workers (32), we did not find an association between À971 and HDL-C. This inconsistency may be explained by the use of a mixed population of women, men, cases and controls selected from the ECTIM cohort, whereas the REGRESS population consisted of only male CAD cases. Accordingly, HDL-C levels differed largely between these two populations. However, this discrepancy and other inconsistent observations in our and other cohorts with respect to associations of TaqIB and À629 with CETP concentration or HDL-C (17, 19, 20, 32) , teach us that it may prove very difficult to draw general conclusions regarding the value of CETP gene variations while using epidemiological data. We are convinced, however, that the use of well-characterized homogenous populations is imperative for identifying putative functional polymorphisms, as the influence of (unknown) confounding factors is in all probability reduced.
To the best of our knowledge, this is one of the first studies investigating phenotypic associations of a cluster of tightly linked polymorphisms using haplotype analyses in unrelated subjects. Our data clearly subscribe that a detailed analysis of a larger number of polymorphisms is necessary to appoint functional variants (41, 42) . More specifically, our analyses show that 2-pol haplotype models could only be used in combination with larger haplotype models to reveal the complex associations between CETP gene polymorphisms and CETP concentration. This is for instance illustrated by the significant effect of TaqIB on CETP concentration observed in the 2-pol haplotype models consisting of TaqIB and either À2708 or À971. Neither in the stepwise multiple regression procedure of five polymorphisms nor in the comparison of the haplotype models was TaqIB indicated to have an independent effect on CETP concentration. This allowed us to conclude that in the 2-pol haplotype models TaqIB probably served as a substitute for À629. We did not include all polymorphisms of the À629/TaqIB cluster in our analysis for practical reasons. If reporter gene analyses show that À2708 and À971 do not directly influence CETP gene expression, our haplotype analysis needs to be extended to additional polymorphisms that are in LD. Nevertheless, this approach handed us new tools to unravel the complexity of the relationship between CETP gene polymorphisms and CETP concentration and HDL-C.
It is not clear whether the effect of these polymorphisms on CETP concentration and HDL-C can be extrapolated to the previously observed associations of TaqIB with angiographically assessed progression of CAD and response to pravastatin (14) . We performed similar analysis of genotype effects of these five polymorphisms on mean segment diameter (MSD) and minimum obstruction diameter (MOD) as previously done for TaqIB. These analyses indicated that both À629 and TaqIB had equal effects on progression, and that there was an interaction effect between treatment and genotype at these sites (not shown). The power of subsequent 5-pol stepwise regression and haplotype analyses, however, was not sufficient to resolve whether these associations can be attributed to either À629 or TaqIB (not shown). In the Reykjavik Study, TaqIB explained the risk of MI better than À629 genotype (43) , and it was suggested that the associations of TaqIB with the development of MI are due to linkage disequilibrium of TaqIB to yet another unknown polymorphism. We recently established, however, that baseline CETP concentration was more indicative for the clinical outcome of the REGRESS trial than genetic variation at the TaqIB site (A.H.E.M. Klerkx, G.J. de Grooth, A.H. Zwinderman, J.W. Jukema, J.A. Kuivenhoven, J.J.P. Kastelein, manuscript in preparation). From this, it can be hypothesized that, with regard to clinical outcome, variations in the CETP gene may merely be markers for plasma CETP concentration levels.
In conclusion, we here show that variation at the TaqIB site does not play a role in determining either CETP concentration or HDL-C in the REGRESS population, but instead has served as a useful marker for the effects of tightly linked polymorphisms. Using extensive genotype and haplotype analysis, we have demonstrated that in a cluster of five tightly linked polymorphisms, the À629 promoter polymorphism has independent effects on CETP concentration and HDL-C. Secondly, variations located at À2708 and at À971 in the CETP promoter were identified as putatively functional sites that may act together with À629 in determining CETP concentration in an independent cumulative and interactive manner, respectively. Further in vitro functional analysis of these polymorphisms will be critical to provide better insight into the complex regulation of CETP gene expression, and will help to understand the mechanisms that underlie the observed phenotype-genotype associations.
MATERIALS AND METHODS
Study subjects
Subjects were participants in the Regress Growth and Evaluation Statin Study (REGRESS), which was designed to assess the effect of pravastatin on progression of coronary atherosclerosis (27) . In short, all patients were Dutch Caucasians males less than 70 years of age who presented an obstruction of at least 50% of a major coronary artery as assessed by quantitative coronary angiography, and had total cholesterol levels between 4 and 8 mmol/l and plasma triglyceride levels under 4 mmol/l. Patients were treated with either pravastatin (40 mg/day) or placebo for 2 years. All participants gave informed consent.
DNA sequence analysis
Four subjects with the TaqIB B1B1 genotype (presence of the TaqIB restriction site) with relatively high CETP and low HDL-C, and four TaqIB B2B2 subjects with relatively low CETP and high HDL-C levels were selected from the REGRESS study for DNA sequence analysis. In addition, the corresponding DNA sequence of three human genomic library clones (Max-Planck Institute for molecular genetics Berlin, Germany) was determined, namely a YAC clone (ICRFy900G05108D1) and two PAC clones (RPCIP704H20548Q2 and RPCIP704N05733Q2). Standard methods were used for the extraction of genomic DNA from whole blood and plasmid DNA isolation from the YAC and PAC cultures.
To determine the DNA sequence of the region between À3028 and þ1060 of the CETP gene, primers were based on GenBank sequences M32992, AF027656, U71187 and U85248, generating overlapping PCR fragments of approximately 1000 bp. Both strands of the generated PCR products were sequenced with an end primer and an additional internal primer on an automated ABI system using Big Dye Terminator (Applied Biosystems). DNA sequence data were analyzed using GCG (Genetics Computer Group Inc., Madison, WI, USA) and AutoAssembler (Applied Biosystems) software.
Genotype analysis
Genotyping was performed using PCR based restriction fragment length polymorphism analysis. When no disappearance or creation of a restriction site occurred as a result of a newly identified sequence variation, we designed mismatch primers creating forced restriction sites. Table 5 gives the PCR primers, the restriction enzymes used to detect the investigated polymorphisms, and the length of the resulting fragments in the homozygote most and least frequent genotypes. A typical 25 ml PCR reaction mix consisted of 0.1-0.5 mg genomic DNA, 100 nmol/l of each primer, 100 mmol/l of dNTPs and 0.5 units SuperTaq polymerase (HT Biotechnology Ltd, Cambridge, UK) in 1Â SuperTaq buffer (10 mmol/l Tris-HCl, pH 9.0, 1.5 mmol/l MgCl 2 , 50 mmol/l KCl, 0.1% Triton X-100 and 0.01% (w/v) stabilizer). After initial denaturation of the DNA at 94 C for 5 min, the PCR conditions were 94 C for 1 min, 62 C for 1 min and 72 C for 30 s for 30 cycles, followed by 10 min at 72 C. Ten microliters of the PCR sample were digested with two units of the appropriate restriction enzyme following the manufacturer's instructions in a final reaction volume of 20 ml. The restriction fragments were separated by gel electrophoresis on a 2 or 3% agarose gel containing ethidiumbromide and visualized on a UV transilluminator.
Biochemical analysis
The assays for measuring lipid and lipoprotein parameters and a detailed analysis of the lipid variables in the REGRESS study have already been reported elsewhere (14) . Baseline CETP concentration was determined using a two-antibody sandwich immunoassay, which was developed by Niemeijer-Kanters et al. (44) . As a standard, pool plasma containing 2 mg CETP/ml was taken.
Statistical analysis
Genotype associations-Single CETP polymorphism genotype effects on baseline plasma CETP and HDL-C concentration were tested by analysis of variance adjusted for covariates. Multiple CETP polymorphism genotype effects were investigated by a backward regression analysis (P-stay: 0.05) with all five CETP polymorphisms and the covariates in the initial model. Baseline plasma triglyceride concentration was included in the models for the CETP concentration analyses. For the HDL-C concentration analyses, smoking, body mass index and plasma triglyceride concentration were included as covariates. In all analyses, the proportion of variance attributable to the polymorphisms (r 2 ) was calculated as the ratio of the sum of squares due to genotype effects to the total sum of squares. Throughout, P-values < 0.05 were interpreted as significant. All statistical analyses were done with SAS software (version 8, SAS Institute, Cary, NC, USA).
Haplotype associations. Analysis of Hardy-Weinberg equilibrium was performed according to the procedure described by Guo and Thompson (45) and linkage disequilibria between pairs of polymorphic positions were calculated according to the likelihood-ratio test (46) . Both procedures are incorporated in the Arlequin 2.000 software package (47) . The extent of disequilibrium was expressed in terms of (48) .
The haplotype effects were estimated using a method described by Tanck Hum. Genet., in press). In short, haplotypes were assigned to all unambiguous individuals, i.e. those who were homozygous at all polymorphisms or heterozygous at a single polymorphism. For the remaining ambiguous individuals, the haplotype pairs compatible with their genotype were determined and the posterior probabilities were calculated using Bayes' theorem and the maximum likelihood relative haplotype frequencies, which were estimated using the genotype frequencies and an expectation-maximization (E-M) algorithm (49) . These posterior probabilities were used as weights in the statistical model.
The statistical model was basically a linear regression model in which the expected CETP or HDL-C concentration in a subject, ŷ, was assumed to be a linear function of haplotype effects (and effects of confounders):
, where X l (l ¼ 1, . . . , m) attained values 0, 1 or 2 denoting presence of 0, 1 or 2 copies of haplotype l in this subject (m ¼ number of haplotypes estimated to be present in the population). The regression parameter b l represents the average effect of haplotype l on CETP or HDL-C concentration, which under Hardy-Weinberg genotype frequencies is identical to the average excess (50) . Since m was possibly very large, and some haplotypes occurred with very low frequency, the estimated effects of less frequent haplotypes were expected to show a huge variation. To circumvent this problem, we used a penalized log-likelihood approach. Comparable to the 'molecular similarity' approach described by Thomas et al. (51) , we assumed that haplotypes sharing the same alleles would show a similar effect and, secondly, that the extent of this similarity would be related to the number of alleles shared. This way, information available for similar but more frequent haplotypes could be included in the estimation of the effect of the less frequent haplotype, leading to estimates that are more reliable. These assumptions were incorporated in a weighted log-likelihood model by introducing a penalty term (52) , where differences in effects of similar haplotypes were penalized. The optimal magnitude of the penalty term was determined through cross-validation using the generalized cross-validation criterion (53) .
The parameters were estimated using an E-M algorithm. In the E-step, the posterior probabilities of the haplotype pairs were calculated based on the phenotype of the individual subject (in the first E-step, the initial probabilities calculated using the estimated haplotype frequencies were used). In the M-step, the haplotype effects were estimated by solving the first derivative of the penalized log-likelihood function. These two steps were alternated until convergence. The variance of the haplotype effects was estimated using Louis' method (54) .
Next to the five-polymorphism haplotype effects, effects of all possible 'one', two, three and four polymorphism haplotypes were also estimated using the procedure described above. For each haplotype model, the Akaike Information Criterion (AIC) (55) was calculated. Although the penalty had little influence on the ranking of the haplotype models based on the AIC, the reported AICs were calculated in models in which the penalty term was set to zero. Fragments of most frequent (þ) and least frequent (À) alleles are given in base pairs. Generated fragments, which are not variable between the two haplotypes, are given in parentheses.
